Abstract
Psoriasis and systemic lupus erythematosus (SLE) are complex immune-mediated diseases with burdens to patients and society. Recently, there has been considerable progress in understanding of autoimmunity, revealing critical roles for cytokine-mediated pathways that are common to both SLE and psoriasis. Ongoing pharmacogenomic and signaling studies coupled with clinical trials hold promise to better delineate overlaps and divergence in pathogenesis and lead to definition of biomarkers that can predict disease subsets, disease states, organ involvement and responsiveness to treatment. This review will compare SLE and psoriasis with regard to mutually relevant immune pathways and examine their significance as an influx of new biologic treatments comes into use.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call